Cetuximab or bevacizumab with combi chemo equivalent in KRAS wild-type MCRC
Adding cetuximab or bevacizumab to combination chemotherapy improves survival for patients with KRAS wild-type untreated colorectal cancer, with both treatments offering approximately 30-month overall survival. Genetic testing is crucial to determine the benefit of these treatments.